<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04199364</url>
  </required_header>
  <id_info>
    <org_study_id>2535</org_study_id>
    <secondary_id>2019-002923-13</secondary_id>
    <nct_id>NCT04199364</nct_id>
  </id_info>
  <brief_title>Medium vs Low Oxygen Threshold for the Surfactant Administration</brief_title>
  <official_title>Comparison of Two Fraction Oxygen Inspired (FiO2) Thresholds for the Surfactant Administration in Preterm Infants With Respiratory Disease Syndrome: a Single-center Randomized Phase IV Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virgilio Paolo Carnielli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ospedali Riuniti Ancona</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study will be to assess the better fraction inspired oxygen (FiO2) threshold
      for the surfactant treatment in preterm infants with respiratory distress syndrome (RDS)
      randomized to receive exogenous surfactant at 25% or 30% of FiO2 threshold. The pulmonary
      gas-exchanges will be evaluated by oxygen saturation (SpO2) to FiO2 ratio (SFR) and will be
      used to define the better FiO2 threshold for the surfactant treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Exogenous surfactant therapy is an effective treatment of neonatal respiratory distress
      syndrome (RDS) and has been associated with reduced severity of respiratory distress and
      mortality. The 2019 European guidelines for neonatal RDS treatment suggest as the threshold
      of inspired oxygen (FiO2) for the surfactant treatment at 30% for all gestational age, but
      there are no randomized studies that confirm this indication. Some observational studies
      reported that a relevant number of patients who are not routinely treated with surfactant had
      respiratory complications, thus they received exogenous surfactant. To date, the optimal FiO2
      threshold for surfactant administration remains unclear.

      In this single-center, randomized, phase 4 trial, preterm infants (gestational age&lt;36 weeks)
      with RDS will be randomized to receive exogenous surfactant at 25% or 30% of FiO2 threshold.
      According to the unit policy, the exogenous surfactant will be administered by an
      endotracheal tube in intubated infants, or by Intubation-Surfactant-Extubation (InSurE) /
      Less Invasive Surfactant Administration (LISA) methods in infants who will not remain
      intubated. The method used for the surfactant administration will be at the discretion of the
      caring physician.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants and data analyst will be masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Respiratory pulmonary function</measure>
    <time_frame>At day 3 of life</time_frame>
    <description>The oxygen saturation (SpO2) to fraction of inspired oxygen (FiO2) ratio (SFR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endotracheal intubation</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>The need of endotracheal intubation after surfactant administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen therapy</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>The need of oxygen therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Support-1</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>The need of respiratory support</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory Support-1</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>Oxygenation index as indicator of the intensity of ventilatory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory severity-1</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>Silvermann score as secondary respiratory severity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory severity-2</measure>
    <time_frame>At day 3, 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first</time_frame>
    <description>Lung ultrasound score (LUS) score as secondary respiratory severity index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Long-term respiratory pulmonary function</measure>
    <time_frame>At day 7 and 28 of life, and at 36 weeks of postmenstrual age or at the discharge if it occurs first, and 1 year of corrected age</time_frame>
    <description>The oxygen saturation (SpO2) to fraction of inspired oxygen (FiO2) ratio (SFR)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of prematurity</measure>
    <time_frame>From birth to 36 weeks of postmenstrual age or discharge if it occurred first</time_frame>
    <description>The incidence of intraventricular hemorrhage of grade 3-4, periventricular leukomalacia, bronchopulmonary dysplasia, sepsis and retinopathy of prematurity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>In-hospital death</measure>
    <time_frame>From birth to 36 week of gestation or discharge if it occurred first</time_frame>
    <description>death before 36 weeks of gestation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Respiratory Distress Syndrome</condition>
  <arm_group>
    <arm_group_label>Low FiO2 threshold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fraction of inspired oxygen (FiO2) of 25% to have an oxygen saturation (SpO2) of 90-92%.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medium FiO2 threshold</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A fraction of inspired oxygen (FiO2) of 35% to have an oxygen saturation (SpO2) of 90-92%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Poractant Alfa 80 mg/mL Intratracheal Suspension</intervention_name>
    <description>Exogenous surfactant (Poractant Alfa) administration at a dose of 200 mg/kg.</description>
    <arm_group_label>Low FiO2 threshold</arm_group_label>
    <arm_group_label>Medium FiO2 threshold</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  gestational age less than 36 weeks;

          -  diagnosis of respiratory distress (RDS);

          -  need for ventilatory support;

          -  written informed consent.

        Exclusion Criteria:

          -  congenital malformations;

          -  genetic disorders;

          -  perinatal asphyxia;

          -  withdrawal of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>23 Weeks</minimum_age>
    <maximum_age>36 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valentina Dell'Orto, MD</last_name>
    <phone>0715962014</phone>
    <email>valentinagiovanna.dellorto@ospedaliriuniti.marche.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virgilio Carnielli, MD, PHD</last_name>
    <phone>0715962045</phone>
    <email>virgilio.carnielli@ospedaliriuniti.marche.it</email>
  </overall_contact_backup>
  <reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Te Pas A, Plavka R, Roehr CC, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GHA, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2019 Update. Neonatology. 2019;115(4):432-450. doi: 10.1159/000499361. Epub 2019 Apr 11.</citation>
    <PMID>30974433</PMID>
  </reference>
  <reference>
    <citation>Engle WA; American Academy of Pediatrics Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008 Feb;121(2):419-32. doi: 10.1542/peds.2007-3283.</citation>
    <PMID>18245434</PMID>
  </reference>
  <reference>
    <citation>Jobe AH. Pulmonary surfactant therapy. N Engl J Med. 1993 Mar 25;328(12):861-8. Review.</citation>
    <PMID>8441430</PMID>
  </reference>
  <reference>
    <citation>Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U, Ruzal-Shapiro C, Wung JT, Polin RA. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr. 2005 Sep;147(3):341-7.</citation>
    <PMID>16182673</PMID>
  </reference>
  <reference>
    <citation>Fuchs H, Lindner W, Leiprecht A, Mendler MR, Hummler HD. Predictors of early nasal CPAP failure and effects of various intubation criteria on the rate of mechanical ventilation in preterm infants of &lt;29 weeks gestational age. Arch Dis Child Fetal Neonatal Ed. 2011 Sep;96(5):F343-7. doi: 10.1136/adc.2010.205898. Epub 2011 Jan 30.</citation>
    <PMID>21278432</PMID>
  </reference>
  <reference>
    <citation>Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin CO, Orsini F, Davis PG; Australian and New Zealand Neonatal Network. Incidence and Outcome of CPAP Failure in Preterm Infants. Pediatrics. 2016 Jul;138(1). pii: e20153985. doi: 10.1542/peds.2015-3985.</citation>
    <PMID>27365307</PMID>
  </reference>
  <reference>
    <citation>Pillai MS, Sankar MJ, Mani K, Agarwal R, Paul VK, Deorari AK. Clinical prediction score for nasal CPAP failure in pre-term VLBW neonates with early onset respiratory distress. J Trop Pediatr. 2011 Aug;57(4):274-9. doi: 10.1093/tropej/fmq047. Epub 2010 Jun 16.</citation>
    <PMID>20558382</PMID>
  </reference>
  <reference>
    <citation>Dargaville PA, Aiyappan A, De Paoli AG, Dalton RG, Kuschel CA, Kamlin CO, Orsini F, Carlin JB, Davis PG. Continuous positive airway pressure failure in preterm infants: incidence, predictors and consequences. Neonatology. 2013;104(1):8-14. doi: 10.1159/000346460. Epub 2013 Apr 4.</citation>
    <PMID>23595061</PMID>
  </reference>
  <reference>
    <citation>De Jaegere AP, van der Lee JH, Canté C, van Kaam AH. Early prediction of nasal continuous positive airway pressure failure in preterm infants less than 30 weeks gestation. Acta Paediatr. 2012 Apr;101(4):374-9. doi: 10.1111/j.1651-2227.2011.02558.x. Epub 2012 Jan 9.</citation>
    <PMID>22150698</PMID>
  </reference>
  <reference>
    <citation>Rocha G, Flôr-de-Lima F, Proença E, Carvalho C, Quintas C, Martins T, Freitas A, Paz-Dias C, Silva A, Guimarães H. Failure of early nasal continuous positive airway pressure in preterm infants of 26 to 30 weeks gestation. J Perinatol. 2013 Apr;33(4):297-301. doi: 10.1038/jp.2012.110. Epub 2012 Aug 30.</citation>
    <PMID>22935774</PMID>
  </reference>
  <reference>
    <citation>Gulczyńska E, Szczapa T, Hożejowski R, Borszewska-Kornacka MK, Rutkowska M. Fraction of Inspired Oxygen as a Predictor of CPAP Failure in Preterm Infants with Respiratory Distress Syndrome: A Prospective Multicenter Study. Neonatology. 2019;116(2):171-178. doi: 10.1159/000499674. Epub 2019 May 21.</citation>
    <PMID>31112987</PMID>
  </reference>
  <reference>
    <citation>Sweet DG, Carnielli V, Greisen G, Hallman M, Ozek E, Plavka R, Saugstad OD, Simeoni U, Speer CP, Vento M, Visser GH, Halliday HL. European Consensus Guidelines on the Management of Respiratory Distress Syndrome - 2016 Update. Neonatology. 2017;111(2):107-125. doi: 10.1159/000448985. Epub 2016 Sep 21.</citation>
    <PMID>27649091</PMID>
  </reference>
  <reference>
    <citation>Walsh BK, Daigle B, DiBlasi RM, Restrepo RD; American Association for Respiratory Care. AARC Clinical Practice Guideline. Surfactant replacement therapy: 2013. Respir Care. 2013 Feb;58(2):367-75. doi: 10.4187/respcare.02189.</citation>
    <PMID>23359726</PMID>
  </reference>
  <reference>
    <citation>McCord FB, Curstedt T, Halliday HL, McClure G, Reid MM, Robertson B. Surfactant treatment and incidence of intraventricular haemorrhage in severe respiratory distress syndrome. Arch Dis Child. 1988 Jan;63(1):10-6.</citation>
    <PMID>3279916</PMID>
  </reference>
  <reference>
    <citation>Narendran V, Donovan EF, Hoath SB, Akinbi HT, Steichen JJ, Jobe AH. Early bubble CPAP and outcomes in ELBW preterm infants. J Perinatol. 2003 Apr-May;23(3):195-9.</citation>
    <PMID>12732855</PMID>
  </reference>
  <reference>
    <citation>Hedstrom AB, Gove NE, Mayock DE, Batra M. Performance of the Silverman Andersen Respiratory Severity Score in predicting PCO(2) and respiratory support in newborns: a prospective cohort study. J Perinatol. 2018 May;38(5):505-511. doi: 10.1038/s41372-018-0049-3. Epub 2018 Feb 9.</citation>
    <PMID>29426853</PMID>
  </reference>
  <reference>
    <citation>Pang H, Zhang B, Shi J, Zang J, Qiu L. Diagnostic value of lung ultrasound in evaluating the severity of neonatal respiratory distress syndrome. Eur J Radiol. 2019 Jul;116:186-191. doi: 10.1016/j.ejrad.2019.05.004. Epub 2019 May 7.</citation>
    <PMID>31153563</PMID>
  </reference>
  <reference>
    <citation>Li L, Yang Q, Li L, Guan J, Liu Z, Han J, Chao Y, Wang Z, Yu X. [The value of lung ultrasound score on evaluating clinical severity and prognosis in patients with acute respiratory distress syndrome]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2015 Jul;27(7):579-84. doi: 10.3760/cma.j.issn.2095-4352.2015.07.008. Chinese.</citation>
    <PMID>26138420</PMID>
  </reference>
  <reference>
    <citation>Trachsel D, McCrindle BW, Nakagawa S, Bohn D. Oxygenation index predicts outcome in children with acute hypoxemic respiratory failure. Am J Respir Crit Care Med. 2005 Jul 15;172(2):206-11. Epub 2005 Apr 7.</citation>
    <PMID>15817802</PMID>
  </reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 12, 2019</study_first_submitted>
  <study_first_submitted_qc>December 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <last_update_submitted>December 12, 2019</last_update_submitted>
  <last_update_submitted_qc>December 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ospedali Riuniti Ancona</investigator_affiliation>
    <investigator_full_name>Virgilio Paolo Carnielli</investigator_full_name>
    <investigator_title>Director of Neonatology</investigator_title>
  </responsible_party>
  <keyword>RDS</keyword>
  <keyword>Surfactant</keyword>
  <keyword>Threshold</keyword>
  <keyword>Oxygen</keyword>
  <keyword>Preterm</keyword>
  <keyword>Infant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Poractant alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

